# RenovoRx, Inc.: financial statements, quarterly

RNXT · Nasdaq · CIK 1574094 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rnxt.md) · [Financials](/companies/rnxt/financials.md) · [Filings](/companies/rnxt/filings.md) · [Insiders](/companies/rnxt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rnxt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [197](/filings/0001193125-26-224100.md) | [422](/filings/0001193125-26-349190.md) | [266](/filings/0001493152-25-022304.md) | [238 d](/filings/0001193125-26-131928.md) | [563](/filings/0001193125-26-224100.md) | [909](/filings/0001193125-26-349190.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [94.0](/filings/0001193125-26-224100.md) | [152](/filings/0001193125-26-349190.md) | [53.0](/filings/0001493152-25-022304.md) | [28.0 d](/filings/0001193125-26-131928.md) | [84.0](/filings/0001193125-26-224100.md) | [143](/filings/0001193125-26-349190.md) |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | [103](/filings/0001193125-26-224100.md) | [270](/filings/0001193125-26-349190.md) | [213](/filings/0001493152-25-022304.md) | [210 d](/filings/0001193125-26-131928.md) | [479](/filings/0001193125-26-224100.md) | [766](/filings/0001193125-26-349190.md) |
| Research and development | $k | [1,629](/filings/0001493152-24-045137.md) | [775 d](/filings/0001641172-25-001932.md) | [1,257](/filings/0001641172-25-010935.md) | [1,542](/filings/0001641172-25-024020.md) | [1,650](/filings/0001493152-25-022304.md) | [1,576 d](/filings/0001193125-26-131928.md) | [1,642](/filings/0001193125-26-224100.md) | [1,426](/filings/0001193125-26-349190.md) | [1,685](/filings/0001493152-25-022304.md) | [1,501 d](/filings/0001193125-26-131928.md) | [1,228](/filings/0001193125-26-224100.md) | [1,200](/filings/0001193125-26-349190.md) |
| Selling, general and administrative | $k | not reported | not reported | [1,219](/filings/0001641172-25-010935.md) | [1,492](/filings/0001641172-25-024020.md) | [1,178](/filings/0001493152-25-022304.md) | [1,099 d](/filings/0001193125-26-131928.md) | [1,571](/filings/0001193125-26-224100.md) | [1,522](/filings/0001193125-26-349190.md) | [1,728](/filings/0001493152-25-022304.md) | [2,231 d](/filings/0001193125-26-131928.md) | [2,720](/filings/0001193125-26-224100.md) | [2,915](/filings/0001193125-26-349190.md) |
| Operating income | $k | [(2,983)](/filings/0001493152-24-045137.md) | [(1,777) d](/filings/0001641172-25-001932.md) | [(2,476)](/filings/0001641172-25-010935.md) | [(3,034)](/filings/0001641172-25-024020.md) | [(2,828)](/filings/0001493152-25-022304.md) | [(2,632) d](/filings/0001193125-26-131928.md) | [(3,110)](/filings/0001193125-26-224100.md) | [(2,678)](/filings/0001193125-26-349190.md) | [(3,200)](/filings/0001493152-25-022304.md) | [(3,522) d](/filings/0001193125-26-131928.md) | [(3,469)](/filings/0001193125-26-224100.md) | [(3,349)](/filings/0001193125-26-349190.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | [0.0](/filings/0001641172-25-010935.md) | [0.0 d](/filings/0001641172-25-024020.md) | [0.0 d](/filings/0001493152-25-022304.md) | not reported | [0.0](/filings/0001193125-26-224100.md) | [0.0 d](/filings/0001641172-25-024020.md) | [0.0 d](/filings/0001493152-25-022304.md) | [2.0 d](/filings/0001193125-26-131928.md) | [0.0](/filings/0001193125-26-224100.md) | [0.0 d](/filings/0001193125-26-349190.md) |
| Net income | $k | [(1,421)](/filings/0001493152-24-045137.md) | [(3,227) d](/filings/0001641172-25-001932.md) | [(1,076)](/filings/0001493152-25-022304.md) | [(2,389)](/filings/0001493152-25-022304.md) | [(2,471)](/filings/0001493152-25-022304.md) | [(2,878) d](/filings/0001193125-26-131928.md) | [(2,420)](/filings/0001193125-26-349190.md) | [(2,895)](/filings/0001193125-26-349190.md) | [(2,912)](/filings/0001493152-25-022304.md) | [(2,941) d](/filings/0001193125-26-131928.md) | [(3,521)](/filings/0001193125-26-349190.md) | [(2,911)](/filings/0001193125-26-349190.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001493152-24-045137.md) | not reported | [(0.07)](/filings/0001641172-25-010935.md) | [(0.10)](/filings/0001641172-25-024020.md) | [(0.10)](/filings/0001493152-25-022304.md) | not reported | [(0.08)](/filings/0001193125-26-224100.md) | [(0.08)](/filings/0001193125-26-349190.md) | [(0.08)](/filings/0001493152-25-022304.md) | not reported | [(0.09)](/filings/0001193125-26-224100.md) | [(0.06)](/filings/0001193125-26-349190.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001493152-24-045137.md) | not reported | [(0.07)](/filings/0001641172-25-010935.md) | [(0.10)](/filings/0001641172-25-024020.md) | [(0.10)](/filings/0001493152-25-022304.md) | not reported | [(0.08)](/filings/0001193125-26-224100.md) | [(0.08)](/filings/0001193125-26-349190.md) | [(0.08)](/filings/0001493152-25-022304.md) | not reported | [(0.09)](/filings/0001193125-26-224100.md) | [(0.06)](/filings/0001193125-26-349190.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.2](/filings/0001493152-23-040598.md) | [1.2](/filings/0001641172-25-001932.md) | [4.4](/filings/0001493152-24-018704.md) | [11.7](/filings/0001493152-24-031675.md) | [9.6](/filings/0001493152-24-045137.md) | [7.2](/filings/0001193125-26-131928.md) | [14.6](/filings/0001641172-25-010935.md) | [12.3](/filings/0001641172-25-024020.md) | [10.0](/filings/0001493152-25-022304.md) | [7.0](/filings/0001193125-26-349190.md) | [12.4](/filings/0001193125-26-224100.md) | [9.5](/filings/0001193125-26-349190.md) |
| Current assets | $m | not reported | [1.5](/filings/0001641172-25-001932.md) | not reported | not reported | not reported | [7.8](/filings/0001193125-26-131928.md) | [15.7](/filings/0001641172-25-010935.md) | [13.4](/filings/0001641172-25-024020.md) | [11.0](/filings/0001493152-25-022304.md) | [7.9](/filings/0001193125-26-349190.md) | [13.7](/filings/0001193125-26-224100.md) | [10.8](/filings/0001193125-26-349190.md) |
| Total assets | $m | [3.5](/filings/0001493152-23-040598.md) | [1.5](/filings/0001641172-25-001932.md) | [4.8](/filings/0001493152-24-018704.md) | [12.0](/filings/0001493152-24-031675.md) | [10.0](/filings/0001493152-24-045137.md) | [8.1](/filings/0001193125-26-131928.md) | [16.0](/filings/0001641172-25-010935.md) | [13.6](/filings/0001641172-25-024020.md) | [11.2](/filings/0001493152-25-022304.md) | [8.1](/filings/0001193125-26-349190.md) | [14.0](/filings/0001193125-26-224100.md) | [11.5](/filings/0001193125-26-349190.md) |
| Current liabilities | $m | [1.6](/filings/0001493152-23-040598.md) | [1.2](/filings/0001641172-25-001932.md) | [1.1](/filings/0001493152-24-018704.md) | [1.3](/filings/0001493152-24-031675.md) | [1.8](/filings/0001493152-24-045137.md) | [1.9](/filings/0001193125-26-131928.md) | [1.7](/filings/0001641172-25-010935.md) | [1.6](/filings/0001641172-25-024020.md) | [1.9](/filings/0001493152-25-022304.md) | [2.0](/filings/0001193125-26-349190.md) | [1.9](/filings/0001193125-26-224100.md) | [1.9](/filings/0001193125-26-349190.md) |
| Total liabilities | $m | [3.5](/filings/0001493152-23-040598.md) | [4.5](/filings/0001641172-25-001932.md) | [3.0](/filings/0001493152-24-018704.md) | [2.7](/filings/0001493152-24-031675.md) | [3.0](/filings/0001493152-24-045137.md) | [3.6](/filings/0001193125-26-131928.md) | [2.9](/filings/0001641172-25-010935.md) | [3.0](/filings/0001641172-25-024020.md) | [3.1](/filings/0001493152-25-022304.md) | [2.7](/filings/0001193125-26-349190.md) | [2.7](/filings/0001193125-26-224100.md) | [2.5](/filings/0001193125-26-349190.md) |
| Shareholders' equity | $m | [0.0](/filings/0001493152-24-045137.md) | [3.0](/filings/0001193125-26-131928.md) | [1.8](/filings/0001493152-25-022304.md) | [9.3](/filings/0001493152-25-022304.md) | [7.1](/filings/0001493152-25-022304.md) | [4.5](/filings/0001193125-26-349190.md) | [13.2](/filings/0001193125-26-349190.md) | [10.6](/filings/0001193125-26-349190.md) | [8.1](/filings/0001493152-25-022304.md) | [5.4](/filings/0001193125-26-349190.md) | [11.3](/filings/0001193125-26-349190.md) | [9.0](/filings/0001193125-26-349190.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,728) d](/filings/0001493152-24-045137.md) | [(2,053) d](/filings/0001641172-25-001932.md) | [(2,204)](/filings/0001641172-25-010935.md) | [(2,297) d](/filings/0001641172-25-024020.md) | [(2,194) d](/filings/0001493152-25-022304.md) | [(2,430) d](/filings/0001193125-26-131928.md) | [(3,381)](/filings/0001193125-26-224100.md) | [(2,302) d](/filings/0001193125-26-349190.md) | [(2,270) d](/filings/0001493152-25-022304.md) | [(3,020) d](/filings/0001193125-26-131928.md) | [(3,709)](/filings/0001193125-26-224100.md) | [(2,867) d](/filings/0001193125-26-349190.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | [2.0](/filings/0001193125-26-224100.md) | [0.0 d](/filings/0001193125-26-349190.md) | [0.0 d](/filings/0001493152-25-022304.md) | [0.0 d](/filings/0001193125-26-131928.md) | [0.0](/filings/0001193125-26-224100.md) | [71.0 d](/filings/0001193125-26-349190.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.1](/filings/0001493152-23-040598.md) | [9.1](/filings/0001493152-24-018704.md) | [10.7](/filings/0001493152-24-031675.md) | [10.7](/filings/0001493152-24-045137.md) | [14.9](/filings/0001641172-25-010935.md) | [24.0](/filings/0001641172-25-024020.md) | [24.9](/filings/0001493152-25-022304.md) | [31.4](/filings/0001193125-26-224100.md) | [36.6](/filings/0001193125-26-349190.md) | [36.6](/filings/0001493152-25-022304.md) | [38.0](/filings/0001193125-26-224100.md) | [47.3](/filings/0001193125-26-349190.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,129,508 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349190.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.